Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.

Authors:
Jian Y; Chang L; Shi MX; Sun Y; Chu XX and 28 more

Journal:
Blood Adv

Publication Year: 2023

DOI:
10.1182/bloodadvances.2023011428

PMCID:
PMC10733092

PMID:
37922425

Journal Information

Full Title: Blood Adv

Abbreviation: Blood Adv

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict-of-interest disclosure: The authors declare no competing financial interests."

Evidence found in paper:

"This study was supported by 10.13039/501100004826Beijing Natural Science Foundation (7212041), Clinical Research Incubation Project (Beijing Chao-Yang Hospital, Capital Medical University, CYFH202208), 10.13039/501100001809National Natural Science Foundation of China (81974011), and National High Level Hospital Clinical Research Funding (2022-PUMCH-B-048)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025